Sun Pharma's Specialty Portfolio and Organon Deal Boost Growth
Sun Pharmaceutical reported significant revenue growth in the September quarter, led by strong sales in India and specialty medicines. The company expects medium-term growth from therapies like Ilumya and ongoing innovative projects. Despite acquisition and litigation costs impacting profitability, domestic market share rose to 8.6%. R&D investments are set to increase in the second half of FY27 as development accelerates.
ET Markets·


